Hydrogenology
Hydrogenology editorial study record

Hydrogen-rich saline mitigates pressure-overload-induced cardiac hypertrophy and atrial fibrillation in rats via the JAK-STAT signalling pathway

Wang C, Pan Z. · J Int Med Res. 2020;48(8):300060520936415.

PreclinicalOther formsPublished 2020
Study record, not medical adviceThis page reports one source and Hydrogenology’s source-text extraction. It does not establish that molecular hydrogen is effective, safe or appropriate for any person. Human, animal and laboratory evidence must not be treated as equivalent.
Source and classification

What kind of evidence is this?

Evidence stream

Preclinical

Reported design

Controlled rat abdominal-aortic-constriction experiment plus cultured cardiomyocyte experiments

Research topic

Cardiovascular and circulatory health

Administration classification

Other forms

Study result signal

Not reported in this record.

Outcome type

Not reported in this record.

Reported in the source

Methods at a glance

Population or model

Rats with pressure overload and cultured neonatal rat cardiomyocytes with cardiotrophin-1-induced hypertrophy

Sample

81 rats: sham n=23, aortic-constriction n=19, low-dose H₂ saline n=19 and high-dose H₂ saline n=20

Duration

Six weeks in the rat experiment

Intervention

0.6 mmol/L hydrogen-rich saline at 3 or 6 mL/kg intraperitoneally every day; cells received H₂-rich medium

Hydrogen form

H₂ dissolved in saline or culture medium — H₂ only, not Brown’s gas and not inhalation.

H₂ specification

0.6 mmol/L dissolved H₂.

H₂ flow

Not applicable — intraperitoneal saline and culture medium, not gas inhalation.

O₂ delivered with H₂

No O₂ was co-delivered as part of the intervention.

Comparator

Sham, pressure-overload plus ordinary saline and cultured-cell controls

Reported, not endorsed

Outcomes and reported result

Outcomes measured

Heart and atrial weights, atrial-fibrillation inducibility and duration, fibrosis and JAK-STAT signaling

Reported result

The article reports less cardiac hypertrophy, atrial fibrosis and atrial-fibrillation incidence and duration at both H₂-saline doses, with JAK-STAT down-regulation.

Results-extraction completeness

The complete open-access article was checked for concentration, allocation, doses, duration, principal results, funding and conflicts.

A reported association, difference or mechanism is not automatically a clinical benefit. Null findings, outcome type, study design and precision all matter.

Interpretation limits

Cautions and applicability

Design and reporting cautions

Preclinical pressure-overload model with two doses, induced atrial-fibrillation testing and mechanistic cell experiments. Authors declared no conflicts and no specific grant funding. It is not evidence for treating human hypertrophy or atrial fibrillation.

Applies directly to

Pressure-overload cardiac remodeling in rats and cultured neonatal rat cardiomyocytes.

Preliminary appraisal framework

Not reported in this record.

Preliminary risk-of-bias status

Not reported in this record.

Appraisal rationale

Not reported in this record.

No single-study GRADE certainty rating is assigned. Certainty is assessed by important outcome across a complete eligible evidence set, not by attaching a final grade to one source.

Provenance

Sources and record status

Identifiers

PMID: 32762484 · DOI: 10.1177/0300060520936415

Publisher access

Open-access full text is available through PMC.

Extraction basis

Open-access PMC/publisher full text and PubMed record.

Record revision

2026-08-10